(Q33707081)

28 July 2017

1 reference

title

False positive rates of randomized phase II designs (English)

1 reference

28 July 2017

Liu PY

1

1 reference

28 July 2017

LeBlanc M

series ordinal

2

1 reference

28 July 2017

Desai M

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

Contemporary Clinical Trials

28 July 2017

1 reference

28 July 2017

20

1 reference

28 July 2017

343-352

1 reference

28 July 2017

4

1 reference

Selection designs for pilot studies based on survival.

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

Design and analysis of multiarm clinical trials with survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900009-4

7 January 2021

10.1016/S0197-2456(99)00009-4

Identifiers

DOI

1 reference

28 July 2017

1 reference